DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Veröffentlichungen und Präsentationen

Möglichkeiten zur Verringerung von Bakteriämierisiken bei Verwendung von getunnelten zentralvenösen Dialysekathetern
Hollenbeck, M. et al., Nephro-News 2014 (6): 13-19

Tunneled Catheters with Taurolidine-Citrate-Heparin Lock Solution Significantly Improve the Inflammatory Profile of Hemodialysis Patients
Fontseré, N. et al., Antimicrob. Agents Chemother. 2014 (58): 4180-4184

Prevention of Hemodialysis Catheter-Related Bloodstream Infection Using an Antimicrobial Lock
Quarello, F. and Forneris, G., Blood Purif. 2002 (1): 87-92

Central Venous Catheters and Catheter Locks in Children With Cancer: A Prospective Randomized Trial of Taurolidine Versus Heparin
Handrup, M.M. Pediatr. Blood Cancer, 2013 (60): 1292-1298

Taurolidine lock is highly effective in preventing catheter-related bloodstream infections on patients on home parenteral nutrition: A heparin-controlled prospective trial
Bisseling, T.M. et al. Clinical Nutrition, 2010 (29): 464-468